Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. (TRVI) priced its initial public offering on May 8, 2019 at $10.00 per share, raising $55M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $177.7M. Leerink Partners was lead-left underwriter, joined by Stifel, BMO Capital Markets and Needham. WilmerHale advised the company and Covington & Burling advised the underwriters.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing nalbuphine ER for neurologically mediated conditions, including chronic pruritus, chronic cough in idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease. Its Phase 2b/3 PRISM trial studies severe pruritus linked to prurigo nodularis.

Status

IPO

Ticker

TRVI

Exchange

Nasdaq Global Market

Priced

May 8, 2019

IPO price

$10.00

Raised

$55M

Market cap at IPO price

$177.7M

First filed

Apr 5, 2019

Underwriters

Leerink Partners, Stifel, BMO Capital Markets and Needham

Company counsel

WilmerHale

Underwriters' counsel

Covington & Burling

Sector

Biotech & pharma

Country / state

CT

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.